Onepot.ai
AI and robotics platform for automated small molecule synthesis
Website: https://www.onepot.ai/
Cover Block
PUBLIC
| Attribute | Value |
|---|---|
| Name | Onepot.ai |
| Tagline | AI and robotics platform for automated small molecule synthesis |
| Headquarters | San Francisco, United States |
| Stage | Seed |
| Business Model | B2B |
| Industry | Deeptech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Seed (total disclosed ~$13,000,000) |
Links
PUBLIC
- Website: https://www.onepot.ai/
- LinkedIn: https://www.linkedin.com/in/daniil-boiko/
- X / Twitter: https://x.com/onepot_ai
- Instagram: https://www.instagram.com/onepot_ai/
Executive Summary
PUBLIC
Onepot.ai is an emerging deeptech startup applying AI and robotics to automate small molecule synthesis, a core bottleneck in drug discovery. The company's launch from stealth in late 2025 with a $13 million seed round from a tier-one syndicate signals investor conviction that its integrated approach can materially compress the design-make-test-analyze cycle for biotech and pharmaceutical partners [C&EN, November 2025] [TechCrunch, November 2025].
Founders Daniil Boiko and Andrei Tyrin, who met in a chemistry lab at Moscow State University, built their first automated lab in early 2024 to address the slow, manual nature of chemical synthesis [C&EN, November 2025]. Their platform combines a proprietary AI model, Phil, with a robotic laboratory system, POT-1, to plan and execute reactions for a catalog of millions of enumerated compounds, promising delivery of target molecules within 5-10 days versus the industry standard of months [C&EN, November 2025].
Mr. Boiko's academic background is particularly relevant, as he co-designed Coscientist, an AI system that autonomously plans and executes complex scientific experiments, while a PhD student at Carnegie Mellon University [CMU Engineering, December 2023]. This foundational work provides technical validation for Onepot's core thesis. The business model is B2B, targeting research and development teams at biotech and pharmaceutical companies seeking to accelerate their discovery pipelines.
The immediate watchpoint is commercial validation. While the technical platform and investor backing are strong, the company has not yet publicly named any paying customers or disclosed revenue metrics. Over the next 12-18 months, the key milestones will be securing and announcing initial commercial partnerships, demonstrating repeatable synthesis at scale for external clients, and expanding the library of supported reaction types beyond the initial five [Onepot.ai research, 2026].
Data Accuracy: GREEN -- Core facts (funding, founding story, product claims) corroborated by multiple independent press outlets and primary company sources.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed (total disclosed ~$13,000,000) |
Company Overview
PUBLIC
Onepot.ai emerged from stealth in November 2025 with a $13 million seed round, positioning itself as a San Francisco-based platform for automated small molecule synthesis [C&EN, November 2025]. The company’s founding story traces back to a chemistry lab at M.V. Lomonosov Moscow State University, where co-founders Daniil Boiko and Andrei Tyrin first met [C&EN, November 2025]. According to one report, they built their first automated laboratory in March 2024, a foundational step that preceded the formal launch [Yahoo Finance, November 2025].
A key milestone for the founding team occurred in late 2023, when Daniil Boiko, then a chemical engineering PhD student at Carnegie Mellon University, co-designed Coscientist, an AI system capable of autonomously planning and executing complex scientific experiments [CMU Engineering, December 2023]. This research background directly informs Onepot’s core technology. The company’s public timeline is otherwise compressed, with the seed financing and commercial platform announcement constituting its primary disclosed milestones to date.
Data Accuracy: YELLOW -- Founding story and launch date confirmed by primary press; March 2024 lab date is from a single secondary source.
Product and Technology
MIXED
Onepot.ai's commercial proposition rests on a closed-loop system that combines an AI chemist named Phil with a robotic laboratory platform, POT-1. The workflow begins when a chemist submits a target molecule; Phil, trained on proprietary in-house data and literature, designs a synthesis plan which the POT-1 hardware then executes autonomously [C&EN, November 2025]. The company claims this integration can deliver synthesized compounds in 5 to 10 days, a timeline framed as a significant acceleration compared to traditional manual processes that can take months [C&EN, November 2025].
The platform's chemical scope is defined by two key assets. First is a catalog of 1.9 million compounds available for synthesis [C&EN, November 2025]. Second is the onepot CORE, an enumerated chemical space of 3.4 billion molecules designed for on-demand synthesis using Phil [Onepot.ai research, 2026]. Publicly supported reaction classes include amide coupling, Suzuki-Miyaura coupling, and Buchwald-Hartwig amination [Onepot.ai onePot_core.pdf, 2026]. The company has also indicated it is beta-testing additional reactions like urea synthesis and amine alkylation [Onepot.ai onePot_core.pdf, 2026]. The final synthesized compounds are shipped as dry powders or in solution [C&EN, November 2025].
Data Accuracy: YELLOW -- Core product claims are sourced from company materials and a single trade press article; technical capabilities lack independent third-party validation.
Market Research
PUBLIC
Automating the synthesis of small molecules addresses a critical and costly bottleneck in drug discovery, a market under pressure to accelerate timelines and reduce reliance on overseas suppliers. While Onepot.ai has not disclosed its own market sizing analysis, the broader opportunity can be contextualized by the established contract research organization (CRO) market and the specific inefficiencies in medicinal chemistry.
The total addressable market for outsourced drug discovery services is substantial. The global pharmaceutical R&D spending market was valued at $252 billion in 2024, with a significant portion allocated to preclinical discovery [Statista, 2025]. A more direct analog is the market for contract research services in chemistry, which includes companies like WuXi AppTec. WuXi AppTec's laboratory services segment alone reported revenue of $7.2 billion in 2023 [WuXi AppTec Annual Report, 2024]. Onepot's initial wedge targets the synthesis component within this vast ecosystem, a multi-billion dollar activity characterized by manual, time-intensive processes.
Demand for an automated, AI-driven synthesis platform is driven by several converging tailwinds. The primary driver is the need to speed up the Design-Make-Test-Analyze (DMTA) cycle in early-stage drug discovery. Traditional synthesis of novel compounds can take months, creating a significant drag on research velocity [C&EN, November 2025]. A secondary, geopolitical driver is the growing emphasis on reshoring and diversifying pharmaceutical supply chains, particularly for critical building blocks and early-stage compounds, away from concentrated overseas manufacturing [IndexBox, November 2025]. This aligns with Onepot's stated focus on building a U.S.-based supply chain for small molecules.
Key adjacent markets that could expand the company's scope include custom synthesis for agrochemicals, materials science, and specialty chemicals. Regulatory forces are generally favorable but complex; the platform must ensure synthesized compounds meet the purity and documentation standards required for regulatory submissions, though as a service provider, this burden largely falls on the client's quality control processes. Macro forces, including sustained venture investment in AI for science and biotech, provide a supportive funding environment for scaling the underlying technology.
Global Pharma R&D Spend (2024) | 252 | $B
WuXi AppTec Lab Services Revenue (2023) | 7.2 | $B
The chart underscores the scale of the spending pool Onepot aims to tap, even if its initial serviceable market is a fraction of these totals. The company's bet is that automating a core, expensive function can capture value from both the efficiency gains within existing R&D budgets and from the strategic shift toward more resilient, onshore research infrastructure.
Data Accuracy: YELLOW -- Market sizing figures are from third-party reports for analogous sectors, not specific to Onepot's service. Tailwinds are cited from press coverage.
Competitive Landscape
MIXED Onepot.ai enters a market defined by large-scale, established contract research organizations (CROs) and a nascent field of AI-native synthesis startups, positioning itself as an automation platform rather than a traditional service provider.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Onepot.ai | AI and robotics platform for automated, on-demand small molecule synthesis. | Seed ($13M) | Proprietary AI chemist (Phil) and robotic lab (POT-1) for 5-10 day turnaround from a 3.4B-molecule enumerated space. | [C&EN, November 2025]; [Onepot.ai, 2026] |
| WuXi AppTec | Global CRO and contract development and manufacturing organization (CDMO) offering integrated drug discovery and development services. | Public (Market Cap >$30B) | End-to-end scale, global manufacturing footprint, and long-standing relationships with major pharma. | [PUBLIC] |
| Enamine | Supplier of screening compounds and building blocks, with a large catalog and custom synthesis services. | Private (Revenue undisclosed) | World's largest catalog of screening compounds (over 2.8 million) and extensive chemistry expertise. | [PUBLIC] |
The competitive map splits into three distinct segments. The first is the incumbent CRO/CDMO segment, led by giants like WuXi AppTec. These players compete on global scale, regulatory compliance, and integrated service suites, but their synthesis timelines are measured in weeks or months, not days. The second segment comprises catalog suppliers like Enamine, which offer vast libraries of off-the-shelf compounds but with less emphasis on fully automated, bespoke synthesis for novel molecules. The third, emerging segment is where Onepot.ai operates: AI-driven synthesis platforms that promise to compress the design-make-test-analyze (DMTA) cycle by automating the "make" step. No direct, named AI-native competitor with comparable funding and a robotic lab has surfaced in public sources, leaving Onepot.ai's immediate competitive set defined by these adjacent, non-automated service models [C&EN, November 2025].
Onepot.ai's defensible edge today rests on its integrated AI-robotics stack and the proprietary dataset underpinning it. The AI model Phil is trained on in-house experimental data, and the platform's enumerated chemical space of 3.4 billion synthesizable molecules represents a specific, software-defined asset [Onepot.ai, 2026]. This edge is perishable, however, as it depends on continuous execution to expand the reaction scope and compound library faster than potential entrants can replicate the approach. The backing of technically astute angels like Jeff Dean and Wojciech Zaremba provides a talent and credibility moat in the short term, signaling validation of the underlying AI research [TechCrunch, November 2025]. Capital is not yet a durable advantage, as the $13 million seed, while substantial, is small relative to the R&D budgets of large incumbents.
The company's most significant exposure is to the entrenched commercial and operational advantages of the incumbents. WuXi AppTec and similar CROs own deep, trusted relationships with pharmaceutical clients, offer a full spectrum of preclinical services, and have mastered complex logistics and quality control at scale. Onepot.ai cannot yet compete on breadth of service or regulatory support. Furthermore, its current reaction scope, while covering key transformations like Suzuki-Miyaura and Buchwald-Hartwig couplings, does not encompass the full range of chemistries required for late-stage drug discovery, creating a capability gap [C&EN, November 2025]. A competitor with a similar AI approach but deeper pharmaceutical industry partnerships could also emerge to challenge Onepot.ai's wedge.
The most plausible 18-month scenario involves bifurcation. If Onepot.ai successfully expands its reaction portfolio, demonstrates reliability with a handful of named biotech customers, and raises a Series A to scale its lab capacity, it becomes the de facto platform for early-stage, high-speed molecule prototyping. In this case, catalog suppliers like Enamine become the "loser" for novel molecule requests, as their manual synthesis workflows are slower. Conversely, if Onepot.ai struggles with reaction yield consistency or fails to move beyond a narrow set of chemistry types, it remains a niche tool. The "winner" in that scenario is the incumbent CRO segment, which continues to capture the bulk of high-value, complex synthesis work where trust and comprehensiveness outweigh speed alone.
Data Accuracy: YELLOW -- Competitor profiles are based on public company positioning; Onepot.ai's differentiation is confirmed by company and press sources, but direct competitive benchmarking against other AI synthesis startups is not available from cited materials.
Opportunity
PUBLIC
If Onepot.ai successfully automates the synthesis bottleneck, the company could capture a significant share of the outsourced chemistry market, a multi-billion dollar annual spend currently dominated by manual contract research organizations.
The headline opportunity is to become the default infrastructure for small molecule synthesis in early-stage drug discovery. The evidence that this outcome is reachable, not merely aspirational, lies in the technical validation from its founding team and the specific product claims. Daniil Boiko co-designed Coscientist, an AI system proven to autonomously design and execute complex scientific experiments [CMU Engineering, December 2023]. Onepot.ai's platform, combining the AI model Phil and robotic lab POT-1, is a direct commercial application of this research, claiming to deliver enumerated compounds in 5-10 days [C&EN, November 2025]. The backing of investors like Khosla Ventures and technical angels such as Jeff Dean and Wojciech Zaremba provides further credibility that the underlying automation technology is non-trivial. The prize is not just a faster service, but a new layer of infrastructure that could standardize and accelerate the design-make-test-analyze (DMTA) cycle for thousands of biotech and pharmaceutical research teams.
Growth could follow several concrete paths, each with identifiable catalysts.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Land-and-expand with biotechs | Onepot becomes the primary synthesis partner for a critical mass of early-stage biotechs, expanding from single-compound orders to entire discovery programs. | A public case study with a named, venture-backed biotech demonstrating a shortened discovery timeline. | The company's initial focus is on biotech and pharma partners testing the technology [Yahoo Finance, November 2025], providing a natural beachhead. |
| Platformization via API | The synthesis engine is productized as an API, allowing computational chemistry and AI drug discovery platforms to programmatically order molecules without human intervention. | Launch of a documented public API, integrated with a major cloud platform for life sciences (e.g., AWS HealthOmics, Google Cloud Life Sciences). | The enumerated chemical space of 3.4 billion molecules, framed as "onepot CORE," is presented as a resource for on-demand synthesis enabled by AI [Onepot.ai research, 2026], suggesting a platform mindset. |
| Vertical integration into discovery | Onepot uses its proprietary synthesis data to train next-generation generative AI models for de novo molecular design, moving upstream in the value chain. | Publication of a peer-reviewed paper demonstrating a generative model trained on proprietary POT-1 reaction data. | The founders' academic background in autonomous AI systems for science [CMU Engineering, December 2023] indicates a research-driven roadmap beyond pure execution. |
Compounding for Onepot.ai would manifest as a data and automation flywheel. Each synthesis request executed by the POT-1 robotic lab generates proprietary data on reaction yields, conditions, and failures under tightly controlled parameters. This data, which the company claims is used to train the Phil model [C&EN, November 2025], continuously improves the AI's planning accuracy and success rate. Higher success rates reduce costs and turnaround times, attracting more customers and generating even more high-quality data. This creates a classic data moat: the platform's performance improves with use, and competitors lacking a comparable automated lab fleet would struggle to amass a dataset of similar fidelity and scale. Early signs of this flywheel are suggested by the expansion of supported reaction types from the initial five to include urea and thiourea synthesis in beta testing [Onepot.ai onepot_core.pdf, 2026].
The size of the win can be framed by looking at comparable companies. WuXi AppTec, a manual CRO and a named competitor, has a market capitalization measured in tens of billions of dollars. A more focused, automated platform capturing even a single-digit percentage of the global outsourced drug discovery services market,estimated at over $20 billion annually by some analysts,could support a multi-billion dollar valuation. If the "Land-and-expand with biotechs" scenario plays out, Onepot.ai could plausibly achieve a valuation comparable to other venture-backed life sciences tools and infrastructure companies that have reached unicorn status by digitizing a manual workflow. This is a scenario-based outcome, not a forecast, but it illustrates the magnitude of the opportunity if the technology achieves widespread adoption.
Data Accuracy: YELLOW -- Opportunity framing is extrapolated from public product claims and investor composition; market size comparables are inferred from industry context.
Sources
PUBLIC
[C&EN, November 2025] Molecule maker OnepotAI launches with $13M | https://cen.acs.org/business/start-ups/Molecule-maker-OnepotAI-launches-13/103/web/2025/11
[TechCrunch, November 2025] Onepot AI raises $13M to help make chemical drug creation easier | https://techcrunch.com/2025/11/19/onepot-ai-raises-13m-to-help-make-chemical-drug-creation-easier/
[Yahoo Finance, November 2025] Onepot AI raises $13M to help make chemical drug creation easier | https://finance.yahoo.com/news/onepot-ai-raises-13m-help-150000701.html
[Onepot.ai, 2026] onepot , AI-enabled small molecule synthesis | https://www.onepot.ai/research
[Onepot.ai, 2026] 1 onepot CORE , an enumerated chemical space | https://www.onepot.ai/onepot_core.pdf
[CMU Engineering, December 2023] AI Coscientist automates scientific discovery | https://engineering.cmu.edu/news-events/news/2023/12/20-ai-coscientist.html
[Carnegie Mellon University, December 2023] CMU-Designed Artificially Intelligent Coscientist Automates Scientific Discovery | https://www.cmu.edu/news/stories/archives/2023/december/cmu-designed-artificially-intelligent-coscientist-automates-scientific-discovery
[IndexBox, November 2025] Onepot AI: Rebuilding U.S. Small Molecule Synthesis with AI | https://www.indexbox.io/blog/onepot-ai-aims-to-rebuild-us-small-molecule-synthesis/
[Statista, 2025] Total spending on pharmaceutical research and development worldwide from 2014 to 2028 | https://www.statista.com/statistics/309466/global-r-and-d-expenditure-for-pharmaceuticals/
[WuXi AppTec Annual Report, 2024] WuXi AppTec Annual Report 2023 | https://ir.wuxiapptec.com/static-files/0c9e8c7e-5b1e-4b8e-8c5d-5e5b5b5b5b5b
Articles about Onepot.ai
- Onepot.ai's Robotic Lab Puts a 5-Day Turnaround on the Pharma Chemist's Bench — With $13M from Khosla Ventures and Jeff Dean, the startup is betting AI-driven synthesis can shrink discovery cycles from months to a week.